About Celtic Biotech
Celtic Biotech is developing innovative therapies for solid malignancies and cancer-related pain. Our objective is to deliver transformative treatments that improve overall survival, enhance quality of life, and remain accessible to patients worldwide.
Our approach leverages bioactive peptides derived from snake venom. These compounds offer a novel pharmacological platform with the potential to yield safe and effective therapies, expanding current treatment paradigms in oncology.
Our research prioritises solid tumours with historically poor prognoses and persistent unmet medical needs, including non-small-cell lung cancer (NSCLC). Although outcomes in NSCLC have improved significantly with the advent of targeted therapies and immunotherapies, a substantial proportion of patients either lack actionable molecular alterations or ultimately develop treatment resistance, underscoring the need for new therapeutic strategies. Similar challenges are observed across other solid tumours, including breast and gastrointestinal cancers, supporting the broader clinical development of novel agents in these settings.
Our lead candidate, CB-24 (crotoxin), is a neurotoxin-derived agent with a proposed mechanism involving selective induction of programmed cell death in malignant cells, while aiming to preserve normal tissue integrity.
